newsfilter
← Latest News
GlobeNewswire·

IRulya Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

  • IRulya Therapeutics Inc. granted restricted stock units representing 83,513 shares to three new employees on November 9, 2026.
  • The grants were issued under the company's 2026 Inducement Plan & approved by the Board to comply with Nasdaq Rule 5635(c)(4).
  • Vesting terms include 25% on the last day of the calendar quarter following the first anniversary of the vesting commencement date, with 6.25% vesting each quarter thereafter.
  • IRulya is developing LAM-001 for pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome post lung transplant, & sarcoidosis associated pulmonary hypertension.
  • A Phase 2a study in PH patients is complete, while Phase 2 studies in BOS & PH-ILD are ongoing, & a Phase 2 study in SAPH is anticipated to begin in Q4 2026.
Company
IRulya Therapeutics Inc.
Keywords
Nasdaq:IRLA, IRulya Therapeutics Inc.